Abstract 121P
Background
Colorectal cancer (CRC) is one of the most common malignancies, which has high morbidity and mortality rates globally. Recent studies have shown that tumor immune microenvironment (TIME) plays an important role in the development of CRC. Regulatory T cells (Tregs), a group of immunosuppressive cells, is significant in TIME. However, the role of Tregs in CRC is still controversial.
Methods
We used single-cell RNA sequencing (scRNA-seq) to profile the immune landscape of CRC, aiming to identify key subtype of Treg in the TIME that contribute to the development of CRC. The role of this key subtype of Treg in CRC prognosis was investigated by survival analyses of data from The Cancer Genome Atlas (TCGA) and multiple immunohistochemistry (mIHC) data of colorectal tumor samples collected from Zhongshan Hospital of Fudan University.
Results
Through scRNA-seq of tumor lesions of 13 patients with CRC, we found a new subtype of Treg, which was presented with high expression of baculoviral IAP repeat containing 3 (BIRC3). We confirmed its existence in colorectal cancer lesions by mIHC. Survival analysis of mIHC data from Zhongshan Hospital showed that Treg with high expression of BIRC3 was related with worse overall survival (OS) in CRC patients (P = 0.015). Survival analysis of TCGA database also reached a consistent result (P = 0.024). Multivariate analyses of both mIHC and TCGA data suggested that high expression of BIRC3 in Treg cells was an independent influencing factor for OS of CRC.
Conclusions
This study reveals that BIRC3 is expressed by Treg cells. High expression of BIRC3 in Treg cells indicates negative prognosis in CRC patients, which may provide a rationale for subsequent drug development and CRC management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract